跳至主要内容
临床试验/NCT06975241
NCT06975241招募中4 期

Determining Contribution of Sex and Genetics to DHA Synthesis Rates Over 12 Weeks of EPA Supplementation in Healthy Individuals

University of Toronto1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2025年5月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
招募中
入组人数
64
试验地点
1
主要终点
Plasma DHA synthesis/turnover rates

研究概览

简要总结

The goal of this clinical study is to learn how fast EPA is converted to other molecules, including DHA, with consideration of biological sex and genetics in healthy humans.

The main questions it aims to answer are:

  • How fast is EPA converted to DHA in blood, and is the conversion rate affected by sex and a specific genotype we previously identified?
  • How do sex and the specific genotypes affect blood DHA levels and other products of DHA in response to dietary EPA?
  • How fast does dietary EPA replace blood EPA and other omega-3 fatty acids, and is the rate affected by sex and genotype?

Participants will be asked to take EPA supplements for 12 weeks and provide a series of venous blood samples over the study duration.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •BMI between 18.5- 30 kg/m2

排除标准

  • •High consumption of n-3 PUFA, including ≥ 2 servings of fish/seafood or EPA/DHA-enriched foods per week
  • •Consumption of any supplements containing ALA/EPA/DHA currently or within the previous 6 months
  • •Allergies to any component of the study supplement (fish, gelatin etc.)
  • •BMI <18.5 kg/m² or >30 kg/m²
  • •Women who are pregnant, breastfeeding or planning on becoming pregnant
  • •Diagnosis with chronic or communicable diseases
  • •Prescription of chronic pharmacological medications (except for oral contraceptives)
  • •High blood pressure (systolic or diastolic blood pressure above 130 or 80mmHg, respectively)
  • •Hypertriglyceridemia (serum > or = 1.69 mmol/l)
  • •Hypercholesterolemia (serum LDL-C > or =5 mmol/l)
  • •Anticipated changes in lifestyle within the next 4 months
  • •Heavy alcohol use (>3 drinks/day)
  • •Major surgery in the last six months

研究组 & 干预措施

EPA Supplementation

Experimental

32 males and 32 females will be enrolled in the EPA supplementation arm, with an equal number of GA+GG and AA genotypes (rs953413 SNP) among males and females.

干预措施: EPA 2.4g/day (Dietary Supplement)

结局指标

主要结局

Plasma DHA synthesis/turnover rates

时间窗: Day 0, 3, 7, 14, 28, 56, 84

Plasma DHA synthesis/turnover rates (nmol/mL/day) by sex and rs953413 ELOVL2 polymorphism will be determined. DHA synthesis/turnover rates will be calculated from frequent sampling of plasma DHA levels and carbon-13 isotope signatures of DHA (δ13C-DHA) over 12 weeks.

次要结局

  • Changes in plasma DHA concentrations (nmol/ml)(Baseline and 12 weeks)
  • Plasma EPA turnover rates (nmol/ml/day)(Day 0, 3, 7, 14, 28, 56, 84)
  • Plasma half-lives of EPA and downstream n-3 PUFAs(Over 12 weeks)
  • Plasma DPAn-3 synthesis/turnover rates (nmol/ml/day)(Day 0, 3, 7, 14, 28, 56, 84)
  • Changes in PUFA derived eicosanoid/docosanoid levels(Baseline, 4 weeks and 12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Adam Metherel

Assistant Professor

University of Toronto

研究点 (1)

Loading locations...

相似试验